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Mutational spectrum of the TSC1 gene in a
cohort of 225 tuberous sclerosis complex patients:
no evidence for genotype-phenotype correlation
Marjon van Slegtenhorst, Senno Verhoef, Anita Tempelaars, Lida Bakker, Qi Wang,
Marja Wessels, Remco Bakker, Mark Nellist, Dick Lindhout, Dicky Halley,
Ans van den Ouweland
Abstract
Tuberous sclerosis complex is an inherited
tumour suppressor syndrome, caused by a
mutation in either the TSC1 or TSC2
gene. The disease is characterised by a
broad phenotypic spectrum that can in-
clude seizures, mental retardation, renal
dysfunction, and dermatological abnor-
malities. The TSC1 gene was recently
identified and has 23 exons, spanning 45
kb of genomic DNA, and encoding an 8.6
kb mRNA. After screening all 21 coding
exons in our collection of 225 unrelated
patients, only 29 small mutations were
detected, suggesting that TSC1 mutations
are under-represented among TSC pa-
tients. Almost all TSC1 mutations were
small changes leading to a truncated pro-
tein, except for a splice site mutation and
two in frame deletions in exon 7 and exon
15. No clear diVerence was observed in the
clinical phenotype of patients with an in
frame deletion or a frameshift or nonsense
mutation. We found the disease causing
mutation in 13% of our unrelated set of
TSC patients, with more than half of the
mutations clustered in exons 15 and 17,
and no obvious under-representation of
mutations among sporadic cases. In con-
clusion, we find no support for a genotype-
phenotype correlation for the group of
TSC1 patients compared to the overall
population of TSC patients.
(J Med Genet 1999;36:285–289)
Keywords: tuberous sclerosis complex; mutations;
genotype-phenotype correlation
Tuberous sclerosis complex (TSC) is an auto-
somal dominant neurocutaneous disorder
characterised by the growth of hamartomas in
many tissues and organs, including brain, skin,
heart, and kidney.1 Common neurological
manifestations including seizures and mental
retardation have their onset during early child-
hood, while cysts and angiomyolipomas in the
kidney mostly become apparent during adult
life. Considerable clinical variation is observed
between as well as within families.2 At least
60% of TSC patients represent sporadic cases,
as they have unaVected parents.3
Linkage analysis has shown locus heterogen-
eity for TSC, with one locus on chromosome 94
and a second locus on chromosome 16.5 About
half of the large families can be linked to the
TSC1 locus on chromosome 9q34 and the
other half to the TSC2 locus on chromosome
16p13.6 7 The TSC1 and TSC2 genes were
identified by positional cloning8 9 and there is
abundant evidence that both genes act as
tumour suppressor genes.10–13
The TSC2 gene consists of 41 exons,
spanning 43 kb of genomic DNA.14 It encodes
a 200 kDa protein, tuberin, which has a
putative GAP activity for rab515 and rap1,16 two
members of the ras superfamily of small
GTPases. The mutational spectrum of TSC2
includes a number of large deletions often dis-
rupting the PKD1 gene as well,17 18 but also
point mutations19–27 and a number of missense
changes.28
The TSC1 gene contains 23 exons and
encodes an 8.6 kb mRNA. It spans 45 kb of
genomic DNA and codes for hamartin, a 1164
amino acid protein of 130 kDa. Analysis of the
amino acid sequence showed a potential coiled
coil domain at the C-terminus but no homo-
logy to tuberin or any other known vertebrate
protein was detected.8
The first report describing the molecular
genetic and phenotypic analysis of the TSC1
gene suggested that all mutations are small
changes, that TSC1 mutations are less com-
mon in sporadically aVected subjects, and that
there is a reduced risk of mental retardation in
TSC1 related disease.29 The goal of this study
was to construct the mutational spectrum of
the TSC1 gene in our collection of TSC
patient samples by Southern blot and SSCP
analysis. This would enable us to determine
whether there is a significant diVerence in the
detection rate between familial and sporadic
cases and whether there is a genotype-
phenotype correlation for the TSC1 group
compared to the overall population of TSC
patients.
Patients and methods
PATIENT SELECTION AND DNA ISOLATION
In this study, 225 unrelated patients with
tuberous sclerosis complex, diagnosed accord-
ing to the criteria of Gomez,1 were included.
Eighty-two patients represented familial cases
(36%) with at least one first degree relative.
Three large families showed linkage to 9q34.7
One hundred and forty-three patients were
designated sporadic cases (64%), in the
absence of an apparent family history of TSC.
Patients with a TSC2 mutation were excluded
from the 225 cases. DNA was isolated from
peripheral blood cells according to standard
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procedures.30 Paternity tests were performed
using the Profile kit from Perkin Elmer.
SOUTHERN BLOTTING ANALYSIS
Genomic DNA (6 µg) of 200 unrelated
patients was digested with four diVerent
restriction enzymes (EcoRI, HindIII, PstI, and
TaqI) and run on a 0.7% agarose gel. Southern
blotting and hybridisation were performed
using standard methods.31 Three cDNA clones
were tested on the blots: a 5'RACE clone which
had been amplified from a fetal brain cDNA
pool (bp 24-1696) (Clontech), an RT-PCR
product (bp 1616-3684) generated from fi-
broblast RNA, and a fetal brain cDNA clone
(bp 4100-8600). The three probes cover the
coding sequence as well as the 5' and 3'
untranslated region of the TSC1 gene.
SSCP ANALYSIS AND DNA SEQUENCING
Sequences of primers used for amplification of
the 21 coding exons of the TSC1 gene are pro-
vided at http://expmed.bwh.harvard.edu/
projects/tsc/. For exon 22, a new intronic
forward primer was designed (5'-
atactaccagcttactttccata-3'). SSCP analysis was
performed according to Orita et al32 and 2 µl of
the PCR product were applied to the Pharma-
cia GenePhor Electrophoresis system. Gels
were run for 2.5 hours at 5°C and 18°C. Run-
ning conditions for two gels were 600 V, 50
mA, and 10 W. Subsequently, bands were visu-
alised using a DNA silver staining kit (Pharma-
cia) in a Hoefer automated gel stainer. Variant
patterns were further characterised by direct
sequence analysis of the PCR products on an
automated DNA sequencer (ABI 377) using
the cycle sequencing dye primer kit (Perkin
Elmer).
ASO HYBRIDISATION
Oligonucleotides for ASO hybridisation were
designed for the mutated and normal se-
quence. ASO hybridisations were performed at
37°C for 30 minutes. Filters were washed to
0.3 × SSC for 10 minutes at 37°C.
Results
SCREENING FOR LARGE ABNORMALITIES
No large insertions or deletions were identified
in the TSC1 gene by Southern analysis in 200
patients. Only in one case (T2965) was an
aberrant restriction pattern in a TaqI digest
detected (fig 1A), but no consistent change was
seen with other enzymes. Comparing the
genomic sequence of the TSC1 gene with the
size of the extra fragment, we were able to
locate the lost TaqI site in exon 15. Sequencing
exon 15 of the TSC1 gene of this patient
showed a C to T substitution at bp position
1719 (fig 1B), resulting in the nonsense muta-
tion R500X. The presence of this mutation was
confirmed by allele specific oligonucleotide
(ASO) hybridisation (fig 1C).
SCREENING FOR SMALLER MUTATIONS
Systematic SSCP analysis was undertaken to
screen the 21 coding exons in the TSC1 gene
for small mutations. In total, 25 diVerent
mutations were found in 29 subjects out of the
set of 225 unrelated patients (table 1). All types
of mutations resulting in a truncated protein
have been observed: small deletions/insertions,
Figure 1 (A) Southern blot of TaqI digested DNA from two unrelated TSC patients,
hybridised with a 5' TSC1 cDNA probe (nt 24-1696). A novel 3 kb fragment is detected in
lane 2, indicated by the arrow. (B) Direct sequence analysis shows the de novo nonsense
mutation C→T (R500X) in a TaqI site in patient T2965. (C) ASO hybridisation of the
R500X mutation in patient T2965 (P) and a control (C). N=normal allele, M=mutant
allele.
Table 1 Mutations identified in the TSC1 gene
Exon Patient code Mutation (nt substitution)
Familial/
sporadic
4 T2545 367delT Familial
5 T1214 W103X (529G→A) Familial
T1817 432-1G→A Sporadic†
7 T1298 814delACT Familial
8 T4715 944insA Familial
T8129 958delG Sporadic†
9 T7806 R249X (966A→T) Sporadic
10 T1207 1210 insT Familial
T3945 1240delA Familial
T9809 Y312X (1157C→A) Sporadic
12 T10301 1473delC Familial
13 T1515‡ 1499delT Familial
15 T2965 R500X (1719C→T) Sporadic
T9886 R509X (1746C→T)§ Sporadic
T3922 1892del23 Sporadic†
T2067 1929delAG*§ Familial
T5913 1978del9 Sporadic†
T2636 2007delT* Sporadic†
T4124 2105delAAAG*§ Sporadic
17 T1197 R692X (2295C→T)§ Familial
T3838 Sporadic†
T3908 Sporadic
T5210 Sporadic†
T10816 Sporadic†
T7659 2318ins28 Sporadic
T4068 2328delCT Sporadic
18 T2077‡ R786X (2577C→T)§ Familial
20 T5406 2729delAACA Familial
T1295 2787delG Familial
nt = nucleotide; *mutation reported before8; †parents tested
negative for the mutation; ‡family linked to chromosome 97;
§recurrent mutation, also identified by other groups.8 29
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nonsense mutations, and splice site mutations.
In addition, eight diVerent missense changes
(table 2) were seen in nine unrelated patients.
Fourteen of the 29 mutations were small
deletions, ranging from 1 to 23 bp. Three of
these mutations have been reported
previously.8 In two patients, we detected in
frame deletions of 3 and 9 bp respectively. In
family T1298, a 3 bp deletion in exon 7 segre-
gated with the disease phenotype and resulted
in a small amino acid change (Asp-Phe to Ile at
position 198) in the protein. The grandparents,
who had no signs of TSC, tested negative for
the mutation. In a sporadic patient (T5913), 9
bp were deleted in exon 15, also leading to a
diVerent protein product (Cys-Lys-Ile-Pro to
Ser at aa position 586). Both parents tested
negative for the mutation. Biological parent-
hood was confirmed for both in frame
deletions. All the other deletions led to a
premature stop codon. Nonsense mutations
were detected in 11 cases; R692X was present
in four sporadic cases and in one family. Three
insertions were identified: a single base pair
substitution in exon 7 and exon 10 in familial
cases, and a duplication of 28 bp in exon 17 in
a sporadic patient. A substitution at a splice site
(bp postition 432-1) was detected in a sporadic
patient, of whom the parents tested negative for
the change. The most downstream mutation
detected is a 1 bp deletion in exon 20 in the
middle of the coiled coil domain of hamartin.
No mutations were found 3' of the coiled coil
domain (aa 719-998).
MISSENSE AND SILENT CHANGES
Nine abnormal SSCP patterns were observed
representing missense or silent changes (table
2). In four cases the change was also found in
the normal population. These polymorphisms
were R190S (present in the unaVected parent
and absent in the aVected parent), E445 (allele
frequency of 16% in the normal population),
H732Y (allele frequency of 0.5%), and A943.
E445, H732Y, and A943 have been reported
before.29 None of the additional missense
abnormalities have been confirmed to repre-
sent the disease causing mutation yet. E51D
probably represents a polymorphism, since the
amino acid change is in a conserved group. For
L191H and M224R, neither parent was
available for testing.
TSC1 MUTATIONS IN FAMILIAL AND SPORADIC
CASES
Eighty-two of our 225 unrelated patients
(36%) had other aVected family members. Of
the 29 mutations, 13 were identified in the 82
familial TSC patients (16%) and 16 in the 143
sporadic cases (11%). Hence, we found no sig-
nificant diVerence in detection rate between
familial and sporadic cases. In half of the spo-
radic cases, both parents were available for
analysis and tested negative for the mutation.
In the other sporadic patients, DNA of both
parents was not available, but there was no
clinical indication of TSC disease in the family.
CLINICAL SYMPTOMS VERSUS TYPE OF MUTATION
Patients with a mutation in the TSC1 gene
were scored for the most frequent skin, brain,
kidney, and heart lesions detected in TSC. A
distinction was made between truncating
mutations detected in TSC1 (deletion, inser-
tion, splice site, and nonsense mutations) and
the in frame deletions in exons 7 and 15 (table
3). Comparing both types of mutations, no
obvious correlation could be detected between
the genotype and phenotype in the TSC
patients. The missense changes were left out of
the analysis, because so far none of them has
been confirmed to represent a disease causing
mutation.
CLINICAL MANIFESTATIONS IN PATIENTS WITH
THE RECURRENT MUTATION R692X
The mutation R692X was present in four spo-
radic TSC patients and in two patients from
the same family. The clinical data of these six
patients are summarised in table 4. Almost all
patients have a history of epilepsy. No renal
lesions were detected, but only two patients are
older than 15, so these results could be biased
by the later onset of cysts and angiomyolipo-
mas. All other symptoms were scored at least
once. The patients with the R692X mutation
do not share an obviously similar phenotype.
Discussion
After screening the 21 coding exons of the
TSC1 gene, 29 mutations were detected, all of
Table 2 Missense and silent changes in the TSC1 gene
Exon Code nt change aa change
4 T5768 374A→C E51D
7 T1486 789C→T R190S*
T4712 793T→A L191H
8 T1524 892T→G M224R
12 T10383 1429C→T S403
14 T2083 1556A→G E445*
15 T5100 2415C→T H732Y*
T8775
22 T1219 3050C→T A943*
*Confirmed polymorphism: E445, H732Y and A943 were
reported before.29 nt = nucleotide, aa = amino acid.
Table 3 Overall summary of clinical features of all patients with mutations in the TSC1
gene. A distinction has been made between patients with a stop mutation and an in frame
deletion
Stop mutation In frame deletion Total
Facial angiofibroma 17/29 3/3 20/32 (63%)
Ungual fibroma 10/26 2/3 12/29 (41%)
Hypomelanotic macule 23/26 4/4 27/29 (93%)
Subependymal nodule 24/28 3/4 27/32 (84%)
Cortical tuber 10/28 2/4 12/32 (38%)
Epilepsy 23/30 2/4 25/34 (74%)
Mental retardation 13/27 1/3 14/30 (47%)
Renal cyst 4/26 0/4 4/30 (13%)
Renal angiomyolipoma 1/26 0/4 1/30 (3%)
Cardiac rhabdomyoma 5/24 1/4 6/28 (21%)
Table 4 Clinical features of patients with mutation R692X
T1197a T1197b T3838 T3908 T5210 T10816 Total
Age 56 15* 14 54 6 3
Facial angiofibroma + + − + − − 3/6 (50%)
Ungual fibroma + − − + − − 2/6 (33%)
Hypomelanotic macule − + + − + + 4/6 (67%)
Subependymal nodules + + − + + + 5/6 (83%)
Cortical tuber − − − − + − 1/6 (17%)
Epilepsy + − + + + + 5/6 (83%)
Mental retardation − − ? − + − 1/5 (20%)
Renal cyst − − ? − − − 0/5 (0%)
Renal angiomyolipoma − − ? − − − 0/5 (0%)
Cardiac rhabdomyoma − − + − + − 2/6 (33%)
*Died aged 15 of giant cell astrocytoma.
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them small changes. The only mutation
detected by Southern blot analysis was the
substitution of a C for T in a TaqI (TCGA)
restriction site, resulting in a stop codon. Since
four diVerent restriction enzymes have been
used to test a selection of our TSC patients on
Southern blots, it is unlikely that large
abnormalities disrupting the TSC1 gene have
remained undetected. Previous mutation stud-
ies in the TSC2 gene have shown a diverse
mutational spectrum including large rear-
rangements, deletions, insertions, and non-
sense and missense mutations. In the TSC2
gene, approximately 10% of the mutations
detected so far were large deletions, often
resulting in disruption of the neighbouring
PKD1 gene as well. A possible explanation for
the lack of large mutations in TSC1 may be the
presence of unknown neighbouring or intra-
genic genes that are essential for embryonic
development and survival. Although all the
mutations detected in the TSC1 gene were
small, we could not confirm any missense
change as the disease causing mutation. Only
one missense mutation in TSC1 has been
reported before by Jones et al (personal
communication), but this de novo change in
the gene appeared not to be the disease causing
mutation. Conversely, a number of missense
mutations have been reported in the TSC2
gene.28 It remains to be explained why the
mutational spectrum of the TSC1 and TSC2
genes is diVerent. Despite the diVerences, most
of the mutations in either TSC1 or TSC2 lead
to a truncated protein, which is in concordance
with a loss of function mechanism. Results
obtained by interaction studies indicate that
hamartin and tuberin function as a complex,33
which supports the phenotypic overlap ob-
served between TSC patients with either a
TSC1 or TSC2 mutation.
So far we have detected a mutation in the
TSC1 gene in 13% of our unrelated TSC col-
lection, screening all of the coding region of the
gene by SSCP analysis. It is likely that this
technique fails to detect all of the mutations
and the promoter region has not been tested
yet. We only detected the disease causing
mutation in two out of three of our families
which were clearly linked to chromosome 9.
This number is too small to give an indication
of the ratio of undetected mutations in the
TSC1 gene, but we expect that for the whole
group of TSC patients, the majority of the
mutations will be found in the TSC2 gene. We
did not observe a significantly larger number of
TSC1 mutations in our familial cases than in
the sporadic population, as was found in a
recent study,29 although it is possible that some
of our patients were misclassified as sporadic,
because in only half of these cases was material
from both parents available.
We found a clustering of mutations in exons
15 and 17, in which 14 out of 29 identified
mutations were present. The high mutation
rate in exon 15 had already been observed
when the TSC1 gene was identified8 and can
be partially explained by the size of the exon
(17% of the coding region). Furthermore, the
high proportion of recurrent mutations de-
tected in exons 15 and 17 suggests that part of
these exons are particularly prone to nucleotide
changes.
The truncating mutations as compared to
the in frame deletions in the TSC1 gene did
not show an obvious diVerence in clinical phe-
notype in the patients, suggesting that there is
no clear correlation between the nature of a
TSC1 mutation and the clinical phenotype.
The six patients with the recurrent mutation
R692X also displayed a wide range of clinical
symptoms. This is comparable to the clinical
diVerences detected within families with TSC.
The phenotypic diVerences in TSC patients
are more likely to be caused by mechanisms
such as a second hit,10–12 somatic mosaicism,18
and modifying genes. The latter has also been
proposed to contribute to the complex pheno-
type in the comparable “monogenic” disease
neurofibromatosis 1 (NF1).34 In conclusion, we
found no support for a diVerent phenotypic
spectrum in patients with a mutation in the
TSC1 gene compared to the overall population
of TSC patients.
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